繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Vyome为其主要临床项目VT-1953提交孤儿药物状态报告

2026-02-11 20:07

  • Acceptance of Orphan Drug Status would confer certain anticipated US Market Exclusivity, R&D tax benefits, and PDUFA fee waiver of approximately $3M
  • Independent third-party assessment estimates a current VT-1953 valuation of approximately $455M today and ~$1B after a successful Phase 3 study
  • FDA interactions planned in Q2 2026 for the Phase 3 protocol based on earlier announced positive Phase 2 results

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。